The infusion services market continues to grow as more care moves out of hospitals and into outpatient clinics and the home. Rising rates of chronic illness, growing use of specialty drugs, and lower-cost treatment options are driving demand across the sector, and investors are taking notice.
Inside Dinan’s Summer 2026 Infusion Services Sector Report, we cover current market trends, recent M&A activity, and the key factors shaping the infusion services space, including the growth of ambulatory infusion centers and home infusion providers.
While specialty infusion therapy does not see as much transaction volume as some other healthcare sectors, several serial acquirers are actively building platforms. Companies like Biomatrix have completed multiple acquisitions in the past year.
As private equity involvement in specialty infusion grows, we expect increased aggregation as sponsor-backed platforms pursue add-ons to broaden geographic coverage, scale clinical capabilities, and strengthen payer/provider relationships.
Overall, specialty infusion therapy M&A remains driven by efforts to consolidate high growth markets, expand service lines across sites of care (home and AIC), and build scalable, compliant operating platforms.
Contact Rob Ullman, Managing Director at Dinan Capital Advisors, for more report insights.